Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Comment by pericles1on Jan 23, 2012 7:56pm
433 Views
Post# 19439330

RE: RE: Oncolytics arranges $15-million bought-dea

RE: RE: Oncolytics arranges $15-million bought-dea

The fact that their are no cheap warrants attached makes this financing reasonable.  Do I like it no, with big news in the near future they could have waited, but if you really are interested in getting a partnership then being in a cash bind is not a good way to get the best deal. If this is successfull without warrants then it tells the big boys that we can take this phase III to completion.

Their is a certain cash level that Brad is comfortable with and when we reach that  level he will put out an offering every time. He will not gamble on the phase III even if he thinks their is a high chance of success. With multiple trial news events coming I do not expect this to affect the stock price for very long. This stock will be news driven in the next few months, IMHO.

 

Bullboard Posts